hey angle, you went to a lot of work and it is clever, but you don't start it with "stock" and "pop" which
Especially when you've got Bach, clock crock, #$%$, dock, frock, flock, ...and onward, endlessly (almost)
happy new year
good stuff, thank you. called the company yesterday, since I hadn't met with McElwrath personally since 2009. A woman (girl, actually) said someone would call me back. so far zippo.
Which brings up a question--and keep in mind, I'm a moron--why are we trying to diminish the results of a genetic defect, when we can't change the genetic defect, in cystic fibrosis, when he could be just killing a bacteria, the superbug, which would be huge for the shareholders, and the world.
angle, don't we need more concern in China over pollution for this to get goin?
There are only 'longs' that know nothing will happen soon to move stock up, so there are potential sellers and no buyers. His performance went well; he received applause. With the lab in Philly, you have to wonder why they don't have Independence Blue Cross. A breakthrough in Alzheimer would move the stock, but from what he said, it doesn't seem like they're close. I thought they were doing something on the therapeutic side, but as I recall--and I could be wrong--there was no mention of it.
And if they get Independence, it should go up a little.
about a year ago when I bought Rosetta at twice this price, their revenues were going gang busters. they were getting some 'blues' and it looked like a microrna no brainer. what happened revenue wise?